A drug discovery company that uses single cell RNA sequencing technology to identify drug targets and develop precision medicines for complex diseases such as autoimmunity and cancer.

Celsius is combining single cell genomic sequencing with their validated machine learning platform to identify the role of individual cell populations and their interactions in disease pathogenesis, which may otherwise be obscured by bulk tissue sequencing approaches. Through partnerships with pharma companies and research institutes, Celsius will accrue thousands of patient samples, resulting in the world’s largest scRNA seq dataset of human diseased tissue. Using their proprietary analysis pipeline, Celsius can use this growing dataset to predict therapeutic efficacy within specific patient subgroups, identify potential relapse mechanisms, and discover novel precision therapies based on unique biological insights that were not discernable through standard approaches.